Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment - Pfizer (NYSE:PFE)

Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment - Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer. The positive news comes as the broader market is experiencing gains, with the S&P 500 up 0.53% today, indicating a favorable environment for stocks. Complete FDA Approval For Mutated Colorectal Cancer The FDA granted full approval to Braftovi (…

FDA grants full approval to Pfizer’s colorectal cancer treatment

The FDA granted full approval to Pfizer’s (NYSE:PFE) BRAFTOVI + cetuximab + fluorouracil‑based chemotherapy for adults with BRAF V600E‑mutant metastatic colorectal cancer, supported by new survival data from the Phase 3 BREAKWATER trial The combination significantly improved progression‑free survival, overall survival, and objective response rates compared with standard chemotherapy regimens Safety findings were consistent with known profiles of…

FDA Grants Traditional Approval to Encorafenib in BRAF-Mutated CRC

Results from the BREAKWATER trial led to the traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy in BRAF-mutated CRC.

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Open the article to view the coverage from The AI Journal